LANNETT CO INC (LCI) Stock Price & Overview
NYSE:LCI • US5160122009
Current stock price
The current stock price of LCI is 0.6855 USD. Today LCI is up by 3.86%. In the past month the price decreased by -59.68%. In the past year, price decreased by -74.42%.
LCI Key Statistics
- Market Cap
- 7.381M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.44
- Dividend Yield
- N/A
LCI Stock Performance
LCI Stock Chart
LCI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LCI. When comparing the yearly performance of all stocks, LCI is a bad performer in the overall market: 97.7% of all stocks are doing better.
LCI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LCI. LCI has a bad profitability rating. Also its financial health evaluation is rather negative.
LCI Earnings
LCI Forecast & Estimates
9 analysts have analysed LCI and the average price target is 4.08 USD. This implies a price increase of 495.19% is expected in the next year compared to the current price of 0.6855.
For the next year, analysts expect an EPS growth of -3.01% and a revenue growth -11.78% for LCI
LCI Groups
Sector & Classification
LCI Financial Highlights
Over the last trailing twelve months LCI reported a non-GAAP Earnings per Share(EPS) of -6.44. The EPS decreased by -129.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LCI Ownership
LCI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.26 | 870.633B | ||
| JNJ | JOHNSON & JOHNSON | 18.1 | 544.587B | ||
| MRK | MERCK & CO. INC. | 22.41 | 278.825B | ||
| PFE | PFIZER INC | 8.85 | 152.448B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.054B | ||
| ZTS | ZOETIS INC | 16.47 | 49.42B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.686B | ||
| VTRS | VIATRIS INC | 5.85 | 16.907B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.09 | 11.216B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.535B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.281B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.098B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.42 | 4.954B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LCI
Company Profile
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 564 full-time employees. The company went IPO on 2002-04-15. The firm markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
Company Info
IPO: 2002-04-15
LANNETT CO INC
1150 Northbrook Drive, Suite 155
Trevose PENNSYLVANIA 19136 US
CEO: Timothy C. Crew
Employees: 564
Phone: 12153339000.0
LANNETT CO INC / LCI FAQ
Can you describe the business of LANNETT CO INC?
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 564 full-time employees. The company went IPO on 2002-04-15. The firm markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
What is the current price of LCI stock?
The current stock price of LCI is 0.6855 USD. The price increased by 3.86% in the last trading session.
Does LCI stock pay dividends?
LCI does not pay a dividend.
What is the ChartMill technical and fundamental rating of LCI stock?
LCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in LANNETT CO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LCI.
What is LANNETT CO INC worth?
LANNETT CO INC (LCI) has a market capitalization of 7.38M USD. This makes LCI a Nano Cap stock.
Who owns LANNETT CO INC?
You can find the ownership structure of LANNETT CO INC (LCI) on the Ownership tab.